Skip to main content
Caplight Logo









Attec Biotech

Attec Biotech

Private
HangzhouHealthcare & Life Scienceshttps://attecbiotech.com

Last Round

Series A

Extension

Feb 2, 2026

Company Overview

Attec Biotech is a biotechnology company that develops protein degradation drugs using autophagy-lysosome targeting chimeras (ATTEC) technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

protein degradationmolecular gluetargeted protein degradationautophagy-lysosome pathwayTPDdrug discoveryprecision medicinepreclinical validationhigh-throughput screeningbiotech drug discoveryundruggable targetstherapeutic pipelinecontract researchbioactivity profilingdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Attec Biotech Comparables

Compare Attec Biotech with similar companies based on industry and business-model similarity.

Attec Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AUTOTAC Bio
88%
Amphista Therapeutics
84%
PAQ Therapeutics
84%

Attec Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 2, 2026
Series AAug 1, 2025
VC RoundJul 18, 2022

Attec Biotech Investors

Notable investors and investment history

Attec Biotech investors
InvestorRounds
CAS StarSeries A Extension
Furong InvestmentSeries A Extension
Ennovation VenturesSeries A Extension
HongShan Capital Group (HSG)VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 18, 2022

    Led by HongShan Capital Group (HSG).

Attec Biotech Filings

Explore SEC and related filing metadata, where available.

Attec Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Attec Biotech's valuation, stock price, and market status.

Is Attec Biotech a public or private company?

Attec Biotech is a private company.

What is the current stock price of Attec Biotech?

Attec Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Attec Biotech worth (valuation)?

Valuation information for Attec Biotech is not publicly available.

Can I buy Attec Biotech stock?

Attec Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Attec Biotech's last funding round?

Attec Biotech's most recent funding round was Series A Extension on February 2, 2026.

Who are the main investors in Attec Biotech?

Key investors in Attec Biotech include HongShan.

Will Attec Biotech IPO soon?

No public IPO plans have been announced for Attec Biotech.

How can I track Attec Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Attec Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHangzhou
Year Founded2019
Last FundingFeb 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?